EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Process Optimization of Novel Boronophenylalanine Liposomes Through Box–Behnken Response Surface Design and Preliminary Evaluation in A549 Lung Carcinoma Cells for Boron Neutron Capture Therapy

Haojie Shi iD, Qianlong Xu iD, Fenglin Li iD, Caiyun Fan iD, Yi Han iD

Molecules · 24.04.2026 · 31 (9) · 1409

DOI: 10.3390/molecules31091409 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 24.04.2026. Verfasst von Haojie Shi und 4 weiteren Autor:innen. Beteiligte Einrichtung: China Institute of Atomic Energy, Beijing 102400, China. Hauptthemen laut MEDLINE: Boron Neutron Capture Therapy, Liposomes, Phenylalanine, Boron Compounds. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Industrial Fund of China Institute of Atomic Energy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Boron neutron capture therapy (BNCT) is a binary targeted radiotherapy that uses boron agents to treat refractory malignancies. This study developed a novel boronophenylalanine (BPA)-loaded liposome doped with o-carborane (CB) for BNCT. We applied response surface methodology (RSM) to identify factors affecting BPA loading and optimized encapsulation efficiency (EE) to minimize BPA loss. In in vitro experiments, these liposomes demonstrated promising characteristics for BNCT. The nanoparticle properties of CB-BPA-Lips remain stable for at least 48 h, and CB-BPA-Lips can effectively reduce the release of the agents loaded within them. Both cell viability assays and apoptosis assays have shown that CB-BPA-Lips have good biocompatibility and a lower inhibitory effect on cell viability than BPA. Cellular boron uptake peaked at 47.3642 ng B/106 cells in A549 lung cancer cells and peaked at 38.8875 ng B/106 cells in Bronchial Epithelium transformed with Ad12-SV40 2B (BEAS-2B) human normal bronchial epithelial cells at 24 h post-treatment, with both exceeding uptake in the BPA control group. Overall, this work presents an optimized liposomal formulation that enhances boron delivery to cancer cells and provides a potential candidate boron agent for BNCT pending in-depth in vivo studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Boron Neutron Capture TherapyLiposomesPhenylalanineBoron CompoundsLung NeoplasmsHumansCell SurvivalA549 CellsCarboranesApoptosisBoronNanoparticles

Stichwörter der Autor:innen

A549 cell linesBBD-RSMBNCTBPACB-BPA-Lipsliposomelung cancero-carborane

Substanzen

LiposomesPhenylalanineBoron CompoundsCarboranes4-boronophenylalanineBoron

Autor:innen und Institutionen

  • China Institute of Atomic Energy, Beijing 102400, China.

ORCID-Profile: Haojie Shi, Qianlong Xu, Fenglin Li, Caiyun Fan, Yi Han

Förderung

  • Industrial Fund of China Institute of Atomic Energy

Zitieren

APA

Shi, H., Xu, Q., Li, F., Fan, C., & Han, Y. (2026). Process Optimization of Novel Boronophenylalanine Liposomes Through Box–Behnken Response Surface Design and Preliminary Evaluation in A549 Lung Carcinoma Cells for Boron Neutron Capture Therapy. Molecules, 31(9), 1409. https://doi.org/10.3390/molecules31091409

Vancouver

Shi H, Xu Q, Li F, Fan C, Han Y. Process Optimization of Novel Boronophenylalanine Liposomes Through Box–Behnken Response Surface Design and Preliminary Evaluation in A549 Lung Carcinoma Cells for Boron Neutron Capture Therapy. Molecules. 2026;31(9):1409. doi:10.3390/molecules31091409

BibTeX
@article{Shi2026,
  author = {Shi, Haojie and Xu, Qianlong and Li, Fenglin and Fan, Caiyun and Han, Yi},
  title = {Process Optimization of Novel Boronophenylalanine Liposomes Through Box–Behnken Response Surface Design and Preliminary Evaluation in A549 Lung Carcinoma Cells for Boron Neutron Capture Therapy},
  journal = {Molecules},
  year = {2026},
  volume = {31},
  number = {9},
  pages = {1409},
  doi = {10.3390/molecules31091409}
}
Kostenlos starten →